drugset / Trial / NCT03739554
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Timeline
- Start
- 2019-01-25
- Primary completion
- 2022-11-15
- Completion
- 2023-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYC065 | Small molecule | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |